We are live on ! Find out more
THRN

Thorne Healthtech, Inc. Common Stock

Delisted

THRN was delisted on the 13th of October, 2023.

45 hedge funds and large institutions have $17.3M invested in Thorne Healthtech, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 4445 (+1)

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

34% less capital invested

Capital invested by funds: $26.2M → $17.3M (-$8.95M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
0.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
15
Reduced
14
Closed
6
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K
Name Holding Trade Value Shares
Change
Change in
Stake
EA
1
Emerald Advisers
Pennsylvania
$3.85M -$8.67K -1,955 -0.2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.15M +$1M +226,454 +35%
EMFAT
3
Emerald Mutual Fund Advisers Trust
Pennsylvania
$3.05M -$8.6K -1,940 -0.2%
BlackRock
4
BlackRock
New York
$2.03M +$217K +48,956 +10%
Bank of America
5
Bank of America
North Carolina
$811K +$191K +43,182 +24%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$807K +$45.5K +10,253 +5%
MA
7
MYDA Advisors
New York
$545K +$665K +150,000 New
State Street
8
State Street
Massachusetts
$428K +$43.2K +9,745 +9%
Northern Trust
9
Northern Trust
Illinois
$381K -$9.85K -2,221 -2%
Rockefeller Capital Management
10
Rockefeller Capital Management
New York
$298K
Bank of New York Mellon
11
Bank of New York Mellon
New York
$236K -$315 -71 -0.1%
SI
12
Scout Investments
Missouri
$222K -$899K -202,701 -77%
AWS
13
Atria Wealth Solutions
New York
$146K +$133K +30,000 +294%
Charles Schwab
14
Charles Schwab
California
$124K
HSBC Holdings
15
HSBC Holdings
United Kingdom
$118K -$33.8K -7,633 -19%
Ameriprise
16
Ameriprise
Minnesota
$114K -$458K -103,355 -77%
Millennium Management
17
Millennium Management
New York
$109K +$133K +30,068 New
Goldman Sachs
18
Goldman Sachs
New York
$98.9K +$6.47K +1,459 +6%
SG Americas Securities
19
SG Americas Securities
New York
$84K -$23.3K -5,257 -19%
Morgan Stanley
20
Morgan Stanley
New York
$68.3K -$50.8K -11,452 -38%
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$61K +$1.08K +243 +1%
Citadel Advisors
22
Citadel Advisors
Florida
$58.9K +$72K +16,236 New
Invesco
23
Invesco
Georgia
$47.1K +$57.6K +12,981 New
Renaissance Technologies
24
Renaissance Technologies
New York
$46K +$2.22K +500 +4%
VF
25
Virtu Financial
New York
$45K +$55.2K +12,457 New

THRN Hedge Fund Activity: Q4 2022 in Review

45 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Thorne Healthtech, Inc. Common Stock (THRN) for Q4 2022, worth a combined $17.3M — down 34% from $26.2M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new THRN positions and 6 closed out — a net gain of 1 holder — while 15 added to existing stakes and 14 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $4.83M sold.

  • 45 institutional investors held Thorne Healthtech, Inc. Common Stock (THRN) as of Q4 2022, up from 44 in Q3 2022.
  • Funds reported $17.3M of Thorne Healthtech, Inc. Common Stock stock for Q4 2022, down 34% quarter-over-quarter.
  • 7 funds opened new Thorne Healthtech, Inc. Common Stock positions in Q4 2022 and 6 closed out, a net change of +1 holder.
  • The largest Thorne Healthtech, Inc. Common Stock buyer in Q4 2022 was Vanguard Group, an estimated $1M added.
  • The largest Thorne Healthtech, Inc. Common Stock seller in Q4 2022 was Driehaus Capital Management, an estimated $4.83M sold.

Based on aggregated 13F filings for Q4 2022.